Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy
© 2013 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd..
OBJECTIVE: The aim of this study was to determine whether the effects of prolonged therapy (≥1 year) with anti-tumor necrosis factor (TNF) agents were sustained on the health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD).
METHODS: A cross-sectional survey of patients with IBD who were treated with anti-TNF agents was performed. Results of the validated HRQoL measures (inflammatory bowel disease questionnaire [IBDQ], EuroQoL-5 dimensions [EQ-5D], health status visual analogue scale [VAS] and the Zung self-rating depression scale) were recorded and compared between patients treated with anti-TNF agents for <1 year and ≥1 year.
RESULTS: A total of 41 patients were finally enrolled in the study. Among them, 11 (26.8%) had received anti-TNF therapy for less than one year with a median duration of 7 months (range 3-11 months), while the other 30 (73.2%) had been treated for ≥1 year with a median duration of 42 months (range 12-104 months). Crohn's disease was the most common type in both groups. None of the mean IBDQ, EQ-5D and EQ-5D plus VAS, or Zung self-rating depression scale scores differed significantly between the two groups of patients.
CONCLUSIONS: Improvements in HRQoL for IBD patients on anti-TNF therapy were sustained for longer than one year. HRQoL measures for IBD patients treated with anti-TNF therapy for <1 year do not differ significantly from those treated for ≥1 year, but a trend towards improved HRQoL measures with prolonged therapy can be obtained.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Journal of digestive diseases - 15(2014), 4 vom: 27. Apr., Seite 174-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sherman, Michael [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.11.2014 Date Revised 17.03.2014 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/1751-2980.12125 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM233997997 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM233997997 | ||
| 003 | DE-627 | ||
| 005 | 20231224100324.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1751-2980.12125 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0780.xml |
| 035 | |a (DE-627)NLM233997997 | ||
| 035 | |a (NLM)24373601 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sherman, Michael |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.11.2014 | ||
| 500 | |a Date Revised 17.03.2014 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2013 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd. | ||
| 520 | |a OBJECTIVE: The aim of this study was to determine whether the effects of prolonged therapy (≥1 year) with anti-tumor necrosis factor (TNF) agents were sustained on the health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD) | ||
| 520 | |a METHODS: A cross-sectional survey of patients with IBD who were treated with anti-TNF agents was performed. Results of the validated HRQoL measures (inflammatory bowel disease questionnaire [IBDQ], EuroQoL-5 dimensions [EQ-5D], health status visual analogue scale [VAS] and the Zung self-rating depression scale) were recorded and compared between patients treated with anti-TNF agents for <1 year and ≥1 year | ||
| 520 | |a RESULTS: A total of 41 patients were finally enrolled in the study. Among them, 11 (26.8%) had received anti-TNF therapy for less than one year with a median duration of 7 months (range 3-11 months), while the other 30 (73.2%) had been treated for ≥1 year with a median duration of 42 months (range 12-104 months). Crohn's disease was the most common type in both groups. None of the mean IBDQ, EQ-5D and EQ-5D plus VAS, or Zung self-rating depression scale scores differed significantly between the two groups of patients | ||
| 520 | |a CONCLUSIONS: Improvements in HRQoL for IBD patients on anti-TNF therapy were sustained for longer than one year. HRQoL measures for IBD patients treated with anti-TNF therapy for <1 year do not differ significantly from those treated for ≥1 year, but a trend towards improved HRQoL measures with prolonged therapy can be obtained | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a inflammatory bowel disease | |
| 650 | 4 | |a inflammatory bowel disease questionnaire | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a tumor necrosis factor | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Gastrointestinal Agents |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 700 | 1 | |a Tsynman, Donald N |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Albert |e verfasserin |4 aut | |
| 700 | 1 | |a Arora, Jyoti |e verfasserin |4 aut | |
| 700 | 1 | |a Pietras, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Messing, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a St Hilaire, Lydia |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Decross, Arthur |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Ashok |e verfasserin |4 aut | |
| 700 | 1 | |a Saubermann, Lawrence |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of digestive diseases |d 2007 |g 15(2014), 4 vom: 27. Apr., Seite 174-9 |w (DE-627)NLM168045079 |x 1751-2980 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2014 |g number:4 |g day:27 |g month:04 |g pages:174-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1751-2980.12125 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2014 |e 4 |b 27 |c 04 |h 174-9 | ||